Related references
Note: Only part of the references are listed.Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis
Nan Zhang et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
Dimitrios Sfairopoulos et al.
EUROPACE (2022)
Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study
Sharen Lee et al.
ACTA DIABETOLOGICA (2021)
Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
Victor Okunrintemi et al.
DIABETES OBESITY & METABOLISM (2021)
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Jiandong Zhou et al.
GUT (2021)
Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease
Gary Tse et al.
JOURNAL OF HYPERTENSION (2021)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
Jonathan Mui et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
Thomas A. Zelniker et al.
CIRCULATION (2020)
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
Michael Boehm et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression
Thomas T. van Sloten et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka et al.
Lancet Diabetes & Endocrinology (2020)
SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
Wen-jie Li et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
Kyoung Jin Kim et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study
Tzu-Lan Huang et al.
PLOS ONE (2019)
Atrial Fibrillation and Diabetes Mellitus JACC Review Topic of the Week
Allen Wang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
Qingmiao Shao et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?: Clues From Laboratory Models and Clinical Trials
Milton Packer
CIRCULATION RESEARCH (2018)
Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs
Yue Fei et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Elisabetta Patorno et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Elisabetta Patorno et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
A Machine Learning Aided Systematic Review and Meta-Analysis of the Relative Risk of Atrial Fibrillation in Patients With Diabetes Mellitus
Zhaohan Xiong et al.
FRONTIERS IN PHYSIOLOGY (2018)
Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
Xiaowei Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Inflammation and atrial fibrillation: A comprehensive review
Panagiotis Korantzopoulos et al.
JOURNAL OF ARRHYTHMIA (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
Cyrus R. Kumana et al.
POSTGRADUATE MEDICAL JOURNAL (2017)
Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits
Xiaowei Zhang et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Molecular and Electrophysiological Mechanisms Underlying Cardiac Arrhythmogenesis in Diabetes Mellitus
Gary Tse et al.
JOURNAL OF DIABETES RESEARCH (2016)
Reactive Oxygen Species, Endoplasmic Reticulum Stress and Mitochondrial Dysfunction: The Link with Cardiac Arrhythmogenesis
Gary Tse et al.
FRONTIERS IN PHYSIOLOGY (2016)
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire et al.
JAMA CARDIOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Glucose Levels and Risk of Dementia
Paul K. Crane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Share Paper
